Dotmatics

KRON TV: AI in Medicine From Research Assistant to Predictive Partner

In a KRON-TV interview, Dotmatics VP Phil Mounteney discusses how AI is evolving from automating data tasks to becoming a predictive partner in drug discovery by identifying new targets, designing molecules, and enabling personalized therapies, thereby accelerating drug development, reducing costs, and expanding patient access to safer, tailored medicines.

KRON TV: AI in Medicine From Research Assistant to Predictive Partner

Latest Blogs

Case Studies

White Papers

Upcoming Events

News

Search

In this featured interview on KRON-TV San Francisco, Dotmatics VP of Science & Technology, Phil Mounteney, shares how artificial intelligence is transforming drug discovery and development. He explains how AI today serves as a “research assistant,” automating data-heavy tasks and accelerating analysis, but in the near future will act as a true research partner by helping predict new drug targets, design molecules, and enable more personalized therapies.

Phil also highlights why speed matters in healthcare, how AI can significantly reduce the cost and time to bring drugs to market, and how these advances will expand access to safer, more tailored medicines for patients worldwide.

Watch the full interview to discover how Dotmatics is helping researchers harness AI to accelerate breakthroughs and shape the future of medicine.

Learn More About Dotmatics

Schedule a meeting with our team to learn more about Luma's AI capabilities.